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Objective: The objectives of this study were to estimate the prevalence of Hepatitis C among 
six Italian Local Health Units (LHUs), to describe patient and antiviral drug characteristics, and 
to estimate the health care consumption rates and related costs for the management of patients 
affected by hepatitis C virus (HCV) infection by using data from routine clinical practice.
Methods: We conducted a retrospective study using administrative databases of six Italian 
LHUs. All patients who had a record related to HCV during the enrollment period (July 1, 2009, 
to December 31, 2014) and who had at least 6 months of data available prior to the first HCV 
record were included. The date of the first record related to HCV during the enrollment period 
was considered as a proxy of diagnosis and used as the index date. Patients were followed from 
the index date up to 1 year, death, or exiting the database. Using the overall cohort of HCV 
adult patients as the numerator, we estimated the prevalence of HCV among six LHUs. The 
denominators were obtained from the National Institute of Statistics (N=1,665,682). We also 
evaluated descriptive patient’s characteristics and treatment patterns, and estimated health care 
consumption rates and related costs for the management of the HCV patients. 
Results: A total of 7,550 patients were analyzed, of whom 57% were male with a mean age of 
57.6±16.4 years. The prevalence of HCV was estimated to be 0.45% (95% confidence interval 
0.44–0.46). During the follow-up period, 78.6% of HCV patients had received no antiviral 
treatment. The annual health care cost associated with HCV infection was €6,022.7 (±7,922.6) 
while the cost specific to HCV care was €3,154.6 (±4,972.0)
Conclusion: Our findings showed that, in the Italian real-world setting, only a small proportion 
of HCV-infected patients received an antiviral treatment. Despite the current low prevalence of 
HCV, the economic impact of such disease remains high. 
Keywords: hepatitis C virus infection, prevalence, antiviral drug, health care resources use, 
real-world data
Introduction
Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV), and it is one 
of the major global causes of death and morbidity.1,2 The true incidence of HCV on a 
global scale is not well known, because acute infection is generally asymptomatic. The 
most recent estimates of disease burden show an increase in seroprevalence over the 
last 15 years to 2.8%, equating to >185 million infections worldwide.1,3 However, HCV 
prevalence is highly variable worldwide.2,4 A recent European review has estimated 
that the prevalence of HCV varies between 2.4% for Western and Central Europe and 
2.9% for Eastern Europe.5 
At present, few data are available on the epidemiology of HCV infections consid-
ering the Italian general population.6–12 In addition, the few Italian studies available 
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were obtained in limited geographic areas and were not 
representative of the whole Italian population.11 The limited 
evidence shows that prevalence of HCV seropositivity was 
higher in Southern (7.3%) and Insular areas than in Central 
(6.1%) and Northern regions (about 1.6%).7 
Approximately 55%–85% of individuals exposed to HCV 
develop chronic infection.2 Overall, 30% of the patients 
chronically infected may progress to cirrhosis in their life-
time, whereas 3%–8% of cirrhotic patients may develop 
hepatocellular carcinoma (HCC) every year.1 According to 
the study conducted by the European Centre for Disease Pre-
vention and Control (ECDC), Italy, has the highest number 
of HCV-positive subjects in Europe and the highest death 
rate from HCC and cirrhosis.4
The therapies available to treat HCV have considerably 
changed over the last 5 years and completely changed the 
disease landscape. Until mid-2013, peg-interferon (peg-
IFN) alfa in combination with ribavirin (RBV) was the only 
treatment option for chronic HCV infection in Italy. In April 
2013, the first generation of direct-acting antivirals (DAAs) 
became available in Italy, which were two protease inhibitors 
(PIs) (boceprevir and telaprevir) for the management of HCV 
in combination with peg-IFN-alfa and RBV.13,14 And more 
recently, in 2016, many new HCV DAAs (such as sofosbuvir, 
simeprevir, daclatasvir, ombitasvir, paritaprevir, ledipasvir) 
have been licensed in Europe, for use as part of combination 
therapies for HCV management, and have shown cure rates 
above 90% as reported by SmPCs, respectively.15
Despite the strong recommendation for treatment for nearly 
all HCV-infected patients, a large percentage of infected indi-
viduals remain undiagnosed and untreated for a considerable 
period of time, putting them at risk of advanced liver disease.16
The management of HCV infection generates a consider-
able economic burden on National Health Service (NHS) in 
Italy,17 and the overall health care resource utilization associated 
with HCV tends to increase with advanced disease states (ie, 
compensated cirrhosis, decompensated cirrhosis, and HCC).9,17
The objectives of this study were 1) to estimate the preva-
lence of HCV among six Italian Local Health Units (LHUs), 
2) to describe patient and antiviral drug characteristics, 3) to 
estimate the health care resources consumption for manage-
ment of the patients affected by HCV infection using data 
from routine clinical practice.
Methods
Data source
The study was conducted using administrative databases 
of six LHUs (Torino, Piemonte; Treviso, Veneto; Grosseto, 
Toscana; Terni, Umbria; Barletta-Andria-Trani, Puglia; and 
Cosenza, Calabria) geographically distributed throughout 
the national territory.18
The databases used were 1) the Health-Assisted Sub-
jects’ Database, containing patients’ demographic data; 
2) the Outpatients and Inpatients Pharmaceutical Database, 
providing information for each medication prescription; 
all drugs prescribed were classif ied according to the 
international Anatomic Therapeutic Classification system 
(ATC codes); 3) the Hospital Discharge Database, includ-
ing all hospitalization data, with the main and secondary 
discharge diagnosis codes classif ied according to the 
International Classification of Diseases, Ninth Revision, 
Clinical  Modification (ICD-9-CM) and Diagnosis-Related 
Group (DRG) reimbursement rate; 4) the diagnostic tests 
and specialist visits database, which includes all informa-
tion about outpatient specialist services and the clinical 
laboratory database. 
The patient code in each database allowed electronic link-
age across all databases. Informed consent is not required for 
using encrypted retrospective information. This study was 
approved by the local ethics committee in each participating 
LHU according to the Italian law regarding the conduct of 
observational analysis.19
Study design and cohort definition
This study was a retrospective cohort study from January 
1, 2009 to December 31, 2015 (study period) that included 
all beneficiaries aged ≥18 years of each LHU with a record 
related to HCV (ie, positive HCV testing or medications for 
HCV) retrieved between July 1, 2009 and December 31, 2014 
(enrollment period) and who had at least 6 months of data 
available prior to the first HCV record.
The date of the first record related to HCV (ie, positive 
HCV testing or medications for HCV or hospital admissions 
for HCV complications) during the enrollment period was 
considered as a proxy of diagnosis and used as the index 
date. Patients were followed up from the index date up to 1 
year, death, or exiting the database, whatever occurred first 
(follow-up period). The clinical characteristics of patients 
enrolled in this study were investigated during 6 months prior 
to the index date (characterization period). 
Study variables
Data on baseline characteristics, including demographics (age 
and gender), medical history (hospital admission, prescribed 
HCV drugs, and profile of comorbidity) were collected during 
the characterization period. The HCV treatments of interest 
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were all IFN-based combinations (ATC code: L03AB) and 
protease inhibitor (PI) combinations with or without IFN 
(boceprevir [ATC code: J05AE12] and telaprevir [ATC code: 
J05AE11]). Cirrhosis and HCC were identified as the presence 
of hospitalizations for cirrhosis or HCC related ([ICD-9 CM 
code: 571.XX] and [ICD-9 CM code: 155.XX], respectively) 
during the characterization period. Liver transplantation was 
identified by the presence of hospitalization with ICD-9-CM 
code: 50.5 (liver transplant ICD-9-CM procedure code) dur-
ing the characterization period. The coinfection with human 
immunodeficiency virus (HIV) was identified by the presence 
of DRG codes: 488-489-490, or HIV related hospitalization 
(ICD-9 CM code: 042.XX) or by use of combined antiretrovi-
ral agents (ATC code: J05A). Finally, hepatitis B virus (HBV) 
was identified as the presence of HBV related hospitalization 
(ICD-9 CM codes: 070.2X, 070.3X). 
Previous use of dermatological (ATC code: D) and 
antianemic drugs (ATC code: B03) was evaluated. The 
patients were also characterized based on hospitalization 
for cardiovascular reasons (ICD-9-CM codes: 410–414) and 
neuropsychological events (ICD-9-CM codes: 290–319). 
Comorbidities were measured using the Charlson Comorbid-
ity Index (CCI)20 that assigns a score to each concomitant dis-
ease identified through treatments and hospitalizations during 
the characterization period; the CCI score reflects a patient’s 
overall health status. This same methodology has been widely 
used as a way to compare disease severity in observational 
retrospective studies when data are unavailable.21
During the follow-up period, the presence of HCV treat-
ments (peg-IFN-based combinations or PI combinations with 
or without IFN) were evaluated. Patients were considered 
treated if they had at least one prescription of HCV drugs 
(only the first HCV medication prescribed was considered 
in this analysis). 
In order to estimate HCV management costs, we esti-
mated the overall consumption of health care resources in the 
12 months after the index date (follow-up period). The health 
care consumptions for hospitalizations, drug treatments, and 
outpatient specialist services were classified as related and 
not related to the disease analysis. The health care consump-
tion rates specifically related to HCV were also estimated; 
these were evaluated as the percentage of patients with at 
least HCV treatments, HCV test, or hospitalization related 
to HCV during the follow-up period.
Statistical analysis
Using the overall cohort of HCV adult patients as the numera-
tor, we estimated the prevalence of HCV among six LHUs 
included in the study. The denominators were obtained 
from the National Institute of Statistics,36 comprised the 
demographic distribution by gender and age of the popula-
tion which were extracted from the LHUs). In particular, 
since the NHS website provides only information about the 
total number of assisted subjects by each LHU, to obtain the 
distribution according to gender and age, we reweighted this 
number according to the population distribution available on 
the National Institute of Statistics website. 
We calculated descriptive statistics of the variables of 
interest by reporting means and standard deviations (mean ± 
SD) for continuous variables; whereas categorical variables 
were expressed as numbers and percentages. A confidence 
interval (CI) for an effect size, with a 95% level of confidence 
was reported. All analyses were performed using STATA soft-
ware version 12.1 (Stata Corp LP, College Station, TX, USA).
Cost analysis
The mean annual health care costs per patient, for the man-
agement of the HCV infection, based on the total resource 
consumption were assessed during the follow-up period. 
The total resource consumption was defined by the sum of 
all: prescribed treatments, outpatient specialist services, and 
hospital admission. Both the overall and specific costs related 
to HCV annualized health care resources were estimated. 
The cost analysis was conducted from the perspective of the 
Italian NHS. The costs are reported in euros (€). Drug costs 
were evaluated using the Italian NHS purchase price. Hos-
pitalization costs were determined by using the DRG tariff. 
The cost of instrumental and laboratory tests was defined 
according to the tariffs applied by regions.  
Results 
During the study enrollment period (2009–2014), we identi-
fied 7,550 patients with a diagnosis of HCV; of whom 57% 
were male with a mean age of 57.6 ± 16.4 years. Figure 1 
shows the details of the inclusion and exclusion criteria of 
the study. 
HCV prevalence in the study population was estimated at 
0.45% (95% CI 0.44–0.46) (denominator was N=1,665,682). 
The geographic distribution of HCV prevalence, among 
the three macro-areas studied, was: 0.26% in Northern 
Italy, 0.49% in Central Italy, and 0.51% in Southern Italy. 
The prevalence of HCV at study enrollment tended to be 
higher in males 0.53% (95% CI 0.51–0.55) than females 
0.38% (95% CI 0.37–0.39). The peak was in middle-age 
and older individuals (0.56% [95% CI 0.54–0.58] and 0.67% 
[95% CI 0.65–0.70] in the 50–60 and 70+ years age group, 
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respectively); while, among those aged 18–29 and 30–49 
years it was 0.13% (95% CI 0.12–0.14) and 0.39% (95% CI 
0.37–0.41), respectively. Patient characteristics and prior 
health care resource utilization are summarized in Table 
1. Mean (SD) patient age at the index date was 57.6 (16.4) 
years. Among patients with HCV, most of them are 50–69 
years (37.7% of all subjects included) followed by 30–49 
years age group (30.5% of all subjects included). 
More than half of patients had one or more comorbidity at 
baseline; the mean (SD) CCI was 1.1 (1.4). Patients affected by 
HIV and/or HBV were about 1%. Patients affected by anemia 
and dermatologic events were 5.1% and 2.5%, respectively, and 
8% had cirrhosis, while about 1% had HCC (Table 1). Four 
patients (0.1%) reported liver transplantation for HCV at base-
line. Ninety-six percent (n=7,247) of patients had not received 
any antiviral treatment during 6 months pre-index date. 
The distribution of patients affected by HCV treated 
and untreated during the follow-up period is shown in 
Figure 2. The majority of HCV patients (n=5,934; 78.6% 
of all patients included) had received no antiviral treat-
ment during the follow-up period. Among treated patients 
(n=1,616; 21.4% of all subjects included), 1,556 patients 
were treated with peg-IFN (with or without RBV) and 
30 patients received PI. Prescriptions for both peg-IFN 
and PI were given to 2% of treated patients. During the 
overall follow-up period, ~42% and 46% of patients had at 
least one hospitalization and diagnostic HCV-related test, 
respectively; while, during the same period, 49% and 70% 
of patients had at least one hospitalization and diagnostic 
test per any cause, respectively.
Figure 1 Flowchart of cohort definition
Abbreviations: HCV, hepatitis C virus; LHU, local health unit.
All beneficiaries of each LHU ≥18 years
N=1,665,682
All beneficiaries of each LHU with a record related to HCV (ie,
positive HCV testing or medications for HCV) retrieved between
July 1, 2009 and December 31, 2014
N=8,217
Patients who had at least 6 months of data available prior to the first
HCV record
N= 7,550
Table 1 Baseline demographic and clinical characteristics of the 
study population (N=7,550)
Characteristics
Age (years)
Mean ± SD 57.6 ± 16.4
18–29 335 (4.4)
30–49 2,307 (30.5)
50–69 2,846 (37.7)
70+ 2,062 (27.3)
Gender
Male 4,308 (57.1)
Charlson comorbidity index, mean (SD) 1.1 ± 1.4
0 3,218 (42.6)
1–2 3,364 (44.5)
3–4 749 (9.9)
5+ 219 (2.9)
Coinfections with HBV or HIV 88 (1.2)
HIV 33 (0.4)
HBV 55 (0.7)
History of hospitalization 
Cardiovascular events 9 (0.1)
Cirrhosis 612 (8.1)
HCC 52 (0.7)
Liver transplantation 4 (0.1)
Neuropsychological events 8 (0.1)
HCV treatment type during 6 months pre-ID  
peg-IFN with or without RBV 289 (3.8)
PI with or without peg-IFN 14 (0.2)
Untreated patients 7,247 (96.0)
Other treatments
Antianemic drugs 385 (5.1)
Dermatological drugs 185 (2.5)
Note: Data shown as n (%) or mean ± SD. 
Abbreviations: SD, standard deviation; HCV, hepatitis C virus; HIV, human 
immunodeficiency virus; HCC, hepatocellular carcinoma; HBV, hepatitis B virus; 
peg-IFN, peg-interferon; RBV, ribavirin; PI, protease inhibitors; ID, index date.
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Annual health care costs for the management of HCV 
patients, based on resource consumption from index date, are 
reported in Figure 3. The overall annual expenditure for the 
management of HCV was €6,022.7 (±7,922.6) per patient, of 
which €2,149.0 (±5,201.9) was for drug treatment, €2,343.4 
(±5,626.6) for hospitalizations, and €1,062.1 (±1,757.9) 
for outpatient specialist services. The health care consump-
tion directly related to HCV health care is also reported in 
 Figure 3. The mean annual cost of hepatitis C-related care 
per patients was €3,154.6 (±4,972.0).
Discussion
HCV infection constitutes an important worldwide public 
health problem that is associated with a substantial socio-
economic burden.2,4,22 Available data indicate that infection 
with HCV varies considerably by country and region.4 
 Nevertheless, the true burden of the disease is not well known 
in many countries, given that HCV testing is not routinely 
done, and the diagnosis often occurs several years after the 
initial infection. Despite the high costs of untreated hepatitis 
C patients, the hepatitis C-related reduction in quality of life, 
a majority of patients with chronic hepatitis C are currently 
untreated in many European countries.23
Our analysis estimated that the prevalence of confirmed 
HCV infection among six LHUs analyzed in the years 2009–
2014 was 0.45/1,665,682 health-assisted individuals. Our data 
differ from those observed in the earlier studies,3,6-8,11,37,38 most 
likely because of the difference in the study design and the 
difference in data sources. Unfortunately, these are mainly 
estimates and not collected data. In addition, HCV prevalence 
is probably underestimated because this infection is mostly 
asymptomatic in the acute phase. Although the prevalence of 
Figure 2 Treatment patterns during the follow-up period
Abbreviations: peg-IFN, peg-interferon; RBV, ribavirin; PI, protease inhibitors.
Untreated
(N=5,934)
Treated
(N=1,616)
PI+peg-IFN PI peg-IFN with or without RBV
96%
2%
2%
Figure 3 Annual health care costs (mean ± standard deviation) for the management of HCV patients, based on resource consumption during the follow-up period
Abbreviation: HCV, hepatitis C virus
€2,149.0 ± 5,201.9
€1,270.1 ± 3,332.7
€1,062.1 ± 1,757.9
€186,9 ± 345.8
€2,343.4 ± 5,626.6
€1,664.2 ± 4,456.7
€2,500
Specifically related to HCV health care consumptionOverall health care consumption
€2,000€1,500€1,000€500€0
Drug treatments
Outpatient
specialist services
Hospitalizations
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HCV in Italy is unknown,11 an active surveillance program 
for symptomatic acute hepatitis cases has reported a rate of 
0.2/100,000 inhabitants in 2015.10 Our findings are in line 
with a recently published nationwide study, which used the 
same methods of analysis as ours in a real-world clinical 
setting. The study conducted by Perrone et al,12 from 2009 
to 2010, showed that the prevalence of HCV among ~2.5 
 million health-assisted individuals was 0.4%. The recent 
study conducted by Lapi et al, analyzing all outpatients aged 
at least 15 years registered in the Italian Health Search IMS 
Health Longitudinal Patient Database from January 1, 2002 to 
June 30, 2013 reported that the prevalence rate of HCV in the 
11-year study period was in the range from 0.24% to 0.50%.24
The epidemiological status of HCV infection among the 
European countries is continuously changing and may vary 
region by region. According to the recent systematic review,25 
in Europe, the HCV prevalence is estimated at 1.7% show-
ing a decrease from that previously reported. The lowest 
prevalence (0.9%) is reported from Western Europe and the 
highest (3.1%) from Central Europe.
The results of our analysis also showed that the HCV preva-
lence appears to increase with age; this trend is in accordance 
with what has already been reported previously in Italian 
studies.11 As expected, the current descriptive data suggest that 
patients with HCV infection at younger age are less likely to 
have chronic hepatitis C than those infected at older ages.26–28
Although the incidence and spread of infection have 
decreased over the last decade both in Italy and in the rest 
of the world, past infection remains a major health problem 
in terms of incidence of terminal liver diseases that arise 
many years after infection. A large proportion of HCV-
infected persons develop chronic HCV infection and are at 
risk for advanced liver fibrosis, HCV-related extra-hepatic 
 complications, cirrhosis, and HCC. The progression to cirrho-
sis is often clinically silent, and some patients are not known 
to have hepatitis C until they present with the complications 
of end-stage liver disease or HCC. Our findings have shown 
that 8% and about 1% of HCV-infected patients had cirrhosis 
and HCC at baseline, respectively. 
Many published studies found that approximately from 5% 
to 20% of persons infected with hepatitis C, if not treated, will 
develop cirrhosis within 20 years.2,29 Other existing literature 
has assessed factors associated with treatment ineligibility 
in the era of interferon-based HCV therapy.30 Particularly, 
financial, logistical, patient-provided relationships and disease 
problems as well as patient-specific variables (ie, comorbidi-
ties, advanced age) all contribute to these low treatment rates.
In this real-world assessment, 78.6% of individuals with 
confirmed HCV infection have not received antiviral treat-
ment. This high proportion of untreated patients could be 
explained by the expected important adverse events and poor 
manageability of the therapies available at the time of the 
study, as well as the fact that physicians/patients were waiting 
for the new generation of the antivirals to arrive in the Italian 
market. At any rate, our findings are consistent with those of 
other Italian studies under real-world circumstances, in the 
literature so far.12,31 Stroffolini et al showed that only 33% of 
evaluated HCV-infected patients were treated with current 
standard of care for hepatitis C.31 A recent retrospective Ital-
ian study revealed that12 patients who have not received HCV 
treatments showed a higher rate of progression of disease than 
patients who underwent therapy; in addition, these results also 
showed that patients receiving no treatment led to an increase 
in health care resources, especially in terms of hospitaliza-
tions. Providing early appropriate therapeutic interventions 
that can prevent liver disease progression related to HCV can 
potentially further reduce the economic burden associated 
with chronic hepatitis infection.32,33
However, the true economic burden of the disease is not 
well known in many countries, because capacity is limited for 
collecting epidemiologic data and it is still reported with no 
information about actual costs incurred by HCV patients.9,11,34 
Our cost analysis suggests that, in an Italian health care set-
ting, the total health care cost associated with HCV infection 
was €6,022.7 (±7,922.6) per patient while the cost specific 
to care HCV was €3,154.6 (±4,972.0) per patient.
A recent review of Marcellusi et al17 reported that the 
total economic burden associated with HCV-induced diseases 
was estimated at €1.06 billion (95% CI €0.61–€1.63); a 
percentage of 60.6% was associated with indirect costs and 
39.4% with direct costs. The differences versus published 
data were possibly due to the different health care settings 
(type of health care coverage), value of reimbursement for 
hospitalizations, drug prices, and analysis perspective.35
Our cohort of patients reflected real clinical practice, and 
the results must be interpreted, taking into account limita-
tions related to the observational nature of the study, based 
on data collected through administrative databases. As a 
consequence, we cannot therefore exclude the possibility 
that we may have underestimated the prevalence of HCV. 
Since the information concerning the comorbidities and the 
information relative to the severity of the pathology are not 
available, a proxy of the comorbidities was used, consider-
ing the use of specific drugs, hospitalizations, exemptions, 
which could implicate an underestimation of such condi-
tions in our study. In addition, the problem of underestima-
tion within the prevalence rates of HCV, cirrhosis, HCC, 
and liver transplantation could be regarding the different 
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identification schemes. The use of DRG or ICD-9 or use 
of medication versus ICD-9 alone may lead to different 
outcomes. No information on the reasons for no-treatment 
was included because the data were not retrievable from the 
data set given their administrative scope. Another limitation 
is represented by the short observational period; for the 
evaluation of outcomes of interest, it would be desirable to 
have a longer time interval and a larger number of patients. 
The results and conclusions of this study are limited to the 
population analyzed.
Conclusion
This study shows that, in the Italian real-world setting, only 
a small proportion of HCV-infected patients received an anti-
viral treatment. Despite the current low prevalence of HCV, 
the economic impact of the disease remains high. Future 
research should focus on a larger number of LHUs and cover 
a longer follow-up period, to ensure national representativity 
and include recently launched HCV treatments. 
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